Abstract: Integrated circuits such as programmable logic devices are provided with hotsocket detection circuitry. The hotsocket detection circuitry monitors signals on data pins and power supply voltages. If the data pins become active before the power supply voltages have reached appropriate levels, a hotsocket condition is identified. When a hotsocket condition is identified, driver circuitry on the integrated circuit can be disabled by a hotsocket signal. The integrated circuit may include multiple blocks of input-output circuitry, each of which includes a local hotsocket circuit that uses global hotsocket and power-on-reset signals in disabling input-output circuitry in that input-output block. A power supply circuit in each input-output block may ensure that the local hotsocket circuit in that input-output block is powered.

Abstract: A level shifter circuit includes first and second transistors that receive a first input signal at control inputs. A level shifted output signal is generated by the first and the second transistors. Third and fourth transistors receive a second input signal at control inputs. The first input signal is an inverse of the second input signal. A first multiplexer circuit is configurable to couple a control input of a fifth transistor to the first and the second transistors. A second multiplexer circuit is configurable to couple a control input of a sixth transistor to the third and the fourth transistors.

Abstract: The invention relates to a process for the enzymatic, stereoselective reduction of ketone compounds to provide chiral alcohols, for example the compound of formula Ib:

Abstract: The present invention relates to a process for the stereoselective enzymatic reduction of 1-halo-2-oxo-3-(protected)amino-4-substituted-butanes utilizing certain species of Rhodococcus and Brevibacterium. The product 1-halo-2-hydroxy-3-(protected)amino-4-substituted-butanes, which are useful as intermediates in the synthesis of compounds that are inhibitors of ACE, renin and HIV proteases, are obtained in high yield and, particularly, in very high diastereomeric purity. The process is advantageously highly selective for the (3S,2R) enantiomer of the product.

Abstract: Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.

Abstract: The present invention relates to a process for the stereoselective enzymatic reduction of 1-halo-2-oxo-3-(protected)amino-4-substituted-butanes utilizing certain species of Rhodococcus and Brevibacterium. The product 1-halo-2-hydroxy-3-(protected)amino-4-substituted-butanes, which are useful as intermediates in the synthesis of compounds that are inhibitors of ACE, renin and HIV proteases, are obtained in high yield and, particularly, in very high diastereomeric purity. The process is advantageously highly selective for the 1S,2S enantiomer of the product.

Abstract: The present invention relates to a process for the stereoselective enzymatic reduction of 1-halo-2-oxo-3-(protected)amino-4-substituted-butanes utilizing certain species of Rhodococcus and Brevibacterium. The product 1-halo-2-hydroxy-3-(protected)amino-4-substituted-butanes, which are useful as intermediates in the synthesis of compounds that are inhibitors of ACE, renin and HIV proteases, are obtained in high yield and, particularly, in very high diastereomeric purity. The process is advantageously highly selective for the 1S,2S enantiomer of the product.